Thomas Bogenrieder

3.6k total citations
63 papers, 2.6k citations indexed

About

Thomas Bogenrieder is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas Bogenrieder has authored 63 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Molecular Biology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Bogenrieder's work include Growth Hormone and Insulin-like Growth Factors (8 papers), Melanoma and MAPK Pathways (6 papers) and Peptidase Inhibition and Analysis (6 papers). Thomas Bogenrieder is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (8 papers), Melanoma and MAPK Pathways (6 papers) and Peptidase Inhibition and Analysis (6 papers). Thomas Bogenrieder collaborates with scholars based in Germany, United States and Austria. Thomas Bogenrieder's co-authors include Meenhard Herlyn, Ulrike Weyer-Czernilofsky, Kapaettu Satyamoorthy, David E. Elder, Dirk J. Ruiter, David M. Nanus, Carola Berking, Christos N. Papandreou, Anthony P. Albino and Valentine M. Macaulay and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Thomas Bogenrieder

60 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Bogenrieder Germany 25 1.2k 1.2k 536 371 342 63 2.6k
Richard Kendall United States 24 1.8k 1.5× 837 0.7× 476 0.9× 324 0.9× 268 0.8× 43 3.0k
Koh‐ichi Nakashiro Japan 34 1.7k 1.4× 1.4k 1.2× 802 1.5× 492 1.3× 494 1.4× 127 3.3k
Eduard Ryschich Germany 26 884 0.7× 1.2k 1.0× 489 0.9× 803 2.2× 301 0.9× 73 2.6k
Xianxian Zheng United States 20 1.7k 1.4× 1.1k 1.0× 524 1.0× 238 0.6× 958 2.8× 30 3.4k
Eduardo Farias United States 29 1.4k 1.2× 774 0.7× 618 1.2× 425 1.1× 212 0.6× 67 2.7k
Anne Hansen Ree Norway 30 1.2k 1.0× 1.3k 1.2× 661 1.2× 235 0.6× 506 1.5× 139 3.2k
S. Aaltomaa Finland 31 1.2k 1.0× 1.3k 1.2× 803 1.5× 342 0.9× 754 2.2× 93 3.0k
Olivier Dormond Switzerland 33 1.7k 1.5× 1.1k 1.0× 584 1.1× 422 1.1× 323 0.9× 72 3.3k
George S. Karagiannis United States 29 1.3k 1.1× 1.3k 1.2× 747 1.4× 620 1.7× 374 1.1× 72 3.3k
Monica Tortoreto Italy 32 2.0k 1.6× 1.3k 1.1× 907 1.7× 396 1.1× 402 1.2× 80 3.3k

Countries citing papers authored by Thomas Bogenrieder

Since Specialization
Citations

This map shows the geographic impact of Thomas Bogenrieder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Bogenrieder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Bogenrieder more than expected).

Fields of papers citing papers by Thomas Bogenrieder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Bogenrieder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Bogenrieder. The network helps show where Thomas Bogenrieder may publish in the future.

Co-authorship network of co-authors of Thomas Bogenrieder

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Bogenrieder. A scholar is included among the top collaborators of Thomas Bogenrieder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Bogenrieder. Thomas Bogenrieder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Macaulay, Valentine M., Simon Lord, Syed A. Hussain, et al.. (2023). A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. British Journal of Cancer. 129(6). 965–973. 3 indexed citations
2.
Rieunier, Guillaume, Xiaoning Wu, Stephanie B. Hatch, et al.. (2021). Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction. Cancer Research. 81(8). 2128–2141. 9 indexed citations
3.
4.
Weyer-Czernilofsky, Ulrike, Marco H. Hofmann, Katrin Friedbichler, et al.. (2020). Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Molecular Cancer Therapeutics. 19(4). 1059–1069. 14 indexed citations
5.
Rieunier, Guillaume, Xiaoning Wu, Valentine M. Macaulay, et al.. (2019). Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis. Clinical Cancer Research. 25(12). 3479–3485. 38 indexed citations
6.
Aleksic, Tamara, Nicki Gray, Xiaoning Wu, et al.. (2018). Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage. Cancer Research. 78(13). 3497–3509. 50 indexed citations
7.
Ritter, Cathrin, Selma Ugurel, Lorenzo Cerroni, et al.. (2017). Non-reproducible sequence artifacts in FFPE tissue: an experience report. Journal of Cancer Research and Clinical Oncology. 143(7). 1199–1207. 9 indexed citations
8.
9.
Ireland, Lucy, Almudena Santos, Muhammad S. Ahmed, et al.. (2016). Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Research. 76(23). 6851–6863. 193 indexed citations
10.
Doi, Toshihiko, Kohei Shitara, Yoichi Naito, et al.. (2016). Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors. Annals of Oncology. 27. vi119–vi119. 2 indexed citations
11.
Tan, Daniel S.W., et al.. (2015). 479TiP Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 26. ix125–ix125.
12.
Bogenrieder, Thomas & Werner Stolz. (2003). [From the New World. Louis A. Duhring and dermatitis herpetiformis].. PubMed. 54(2). 167–72. 2 indexed citations
13.
Klebl, Frank, Cornelia M. Gelbmann, Thomas Bogenrieder, et al.. (2003). Palpatorische und sonographische Detektion von Lymphknotenmetastasen bei lokal fortgeschrittenem malignen Melanom*. Medizinische Klinik. 98(12). 783–787. 3 indexed citations
14.
Girlich, Christiane, Thomas Bogenrieder, K.-D. Palitzsch, J Schölmerich, & G. Lock. (2002). Orofacial granulomatosis as initial manifestation of Crohn's disease: a report of two cases. European Journal of Gastroenterology & Hepatology. 14(8). 873–876. 36 indexed citations
15.
Bogenrieder, Thomas, et al.. (2002). Benign Degos' Disease Developing During Pregnancy and Followed for 10 Years. Acta Dermato Venereologica. 82(4). 284–287. 14 indexed citations
16.
Satyamoorthy, Kapaettu, Thomas Bogenrieder, & Meenhard Herlyn. (2001). No longer a molecular black box – new clues to apoptosis and drug resistance in melanoma. Trends in Molecular Medicine. 7(5). 191–194. 42 indexed citations
17.
Bogenrieder, Thomas, Michael Landthaler, & Wilhelm Stolz. (2001). Airborne contact dermatitis due to chloroacetamide in wall paint. Contact Dermatitis. 45(1). 55–55. 8 indexed citations
18.
Bosserhoff, Anja‐Katrin, et al.. (1998). Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Research. 8(6). 504–509. 30 indexed citations
19.
Papandreou, Christos N., B A Usmani, Yiping Geng, et al.. (1998). Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Medicine. 4(1). 50–57. 234 indexed citations
20.
Papandreou, Christos N., Thomas Bogenrieder, Frank Loganzo, Anthony P. Albino, & David M. Nanus. (1997). Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers. Urology. 49(3). 481–486. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Kendall Breakdown of academic impact, for papers by Koh‐ichi Nakashiro Breakdown of academic impact, for papers by Eduard Ryschich Breakdown of academic impact, for papers by Xianxian Zheng Breakdown of academic impact, for papers by Eduardo Farias Breakdown of academic impact, for papers by Anne Hansen Ree Breakdown of academic impact, for papers by S. Aaltomaa Breakdown of academic impact, for papers by Olivier Dormond Breakdown of academic impact, for papers by George S. Karagiannis Breakdown of academic impact, for papers by Monica Tortoreto
Rankless by CCL
2026